Kolexia
Dumas Pierre-Yves
Oncologie hémato.
Hôpital Haut-lévêque
Pessac, France
153 Activités
45 Followers

Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Leucémie aigüe myéloïde Leucémies Leucémie myéloïde Syndromes myélodysplasiques Maladie résiduelle Leucémie myélomonocytaire chronique Leucémie-lymphome lymphoblastique à précurseurs B et T Maladie aigüe Leucémie myéloïde chronique BCR-ABL positive

Industries

Abbvie
33 collaboration(s)
Dernière en 2023
Astellas
20 collaboration(s)
Dernière en 2023
Celgene
10 collaboration(s)
Dernière en 2023
Janssen
9 collaboration(s)
Dernière en 2023

Dernières activités

Dismal outcome of refractory or relapsing patients with myelodysplasia-related acute myeloid leukemia partially alleviated by intensive chemotherapy.
Cancer medicine   26 février 2024
Performance of Mucorales spp. qPCR in bronchoalveolar lavage fluid for the diagnosis of pulmonary mucormycosis.
Medical mycology   19 février 2024
OGILAR: Open-label, Phase 2 Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia
Essai Clinique (French Innovative Leukemia Organisation)   05 février 2024
Prognostic value of postinduction medullary myeloid recovery by flow cytometry in acute myeloid leukemia.
EJHaem   10 janvier 2024
Artificial intelligence-based prediction models for acute myeloid leukemia using real-life data: A DATAML registry study.
Leukemia research   09 janvier 2024
GATA-2 Project: Retrospective and Prospective Exploratory Study for Characterisation of Predictive Parameters of Clonal Evolution in Subjects With GATA2 Germline Mutation
Essai Clinique (Institut Universitaire du Cancer Toulouse Oncopole)   11 décembre 2023
AGORA-1 /ALFA 2100 Study : A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults With FLT3-ITD Relapse/Refractory (R/R) AML
Essai Clinique (Centre Antoine Lacassagne)   09 novembre 2023
Molecular Relapse after First-Line Intensive Therapy in Patients with Core-Binding Factor and NPM1-Mutated Acute Myeloid Leukemia - a Filo Study
65th ASH Annual Meeting Abstracts   02 novembre 2023
Levofloxacin to Prevent Bacterial Infection in Patients with Acute Myeloid Leukemia Treated By Azacitidine and Venetoclax: A Study from the Dataml Registry
65th ASH Annual Meeting Abstracts   02 novembre 2023
Current Results of Intensive Therapy in Younger Adults with Acute Myeloid Leukemia (AML): The Large Randomized French Backbone Intergroup (BIG)-1 Study on Behalf of the Filo, ALFA, and SFGM-TC Study Groups
65th ASH Annual Meeting Abstracts   02 novembre 2023